Home » Stocks » Vaxcyte

Vaxcyte, Inc. (PCVX)

Stock Price: $37.48 USD -1.02 (-2.65%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $37.52 +0.04 (0.11%) Aug 11, 4:29 PM

Stock Price Chart

Key Info

Market Cap 1.90B
Revenue (ttm) n/a
Net Income (ttm) -50.27M
Shares Out 50.73M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $37.48
Previous Close $38.50
Change ($) -1.02
Change (%) -2.65%
Day's Open 40.00
Day's Range 36.63 - 40.00
Day's Volume 320,913
52-Week Range 17.80 - 43.93

More Stats

Market Cap 1.90B
Enterprise Value 1.84B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 50.73M
Float 3.82M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -12.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 198,363
Short Ratio 0.08
Short % of Float 0.04%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 12.75
Revenue n/a
Operating Income -54.15M
Net Income -50.27M
Free Cash Flow -48.34M
Net Cash 58.98M
Net Cash / Share 1.16
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(15.39% upside)
Current: $37.48
Target: 43.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-54.15-35.53
Net Income-50.27-29.49
Shares Outstanding3.983.63
Earnings Per Share-13.25-8.12
Operating Cash Flow-47.15-30.47
Capital Expenditures-1.20-1.77
Free Cash Flow-48.34-32.24
Cash & Equivalents58.9866.09
Total Debt-0.16
Net Cash / Debt58.9865.93
Book Value-106-57.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vaxcyte, Inc.
Country United States
Employees 43
CEO Grant E. Pickering

Stock Information

Ticker Symbol PCVX
Stock Exchange NASDAQ
Unique Identifier NASDAQ: PCVX
IPO Date June 12, 2020


Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.